Novartis AG (SWX:NOVN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 234.28B +19.6% |
| Revenue (ttm) | 45.81B +2.7% |
| Net Income | 10.31B -6.6% |
| EPS | 5.34 -3.4% |
| Shares Out | 1.90B |
| PE Ratio | 23.06 |
| Forward PE | 16.80 |
| Dividend | 3.70 (2.91%) |
| Ex-Dividend Date | Mar 10, 2026 |
| Volume | 4,912,744 |
| Open | 129.02 |
| Previous Close | 123.26 |
| Day's Range | 127.42 - 132.48 |
| 52-Week Range | 96.03 - 132.48 |
| Beta | 0.49 |
| Analysts | Hold |
| Price Target | 123.74 (-5.51%) |
| Earnings Date | Oct 27, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for NOVN stock is "Hold." The 12-month stock price target is CHF 123.74, which is a decrease of -5.51% from the latest price.
News
H.C. Wainwright says Novartis success in RMS trials does not impact TG’s Briumvi
After Novartis (NVS) announced topline data from the REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis, H.C. Wainwright analyst Emily Bodnar believes that remibrutinib will be favore...
Novartis Reported Encouraging Trial Data for a Multiple Sclerosis Drug. The Stock Is Jumping
Promising results from a recent clinical trial are boosting Novartis shares this morning.
Novartis Stock (NVS) Pops as Multiple Sclerosis Drug Shows Positive Results in Late-Stage Trials
Novartis ($NVS) stock rose about 6% at the time of writing on Tuesday, after the Swiss drugmaker reported positive results from two late-stage trials of remibrutinib in relapsing multiple sclerosis.
Why Novartis Stock Is Heading for Its Best Day Since 2023 After 3 Patient Deaths
Novartis says it has paused clinical trials for rap-cel in patients with autoimmune disease, while reporting positive data for a different potential blockbuster.
Sandisk, Marvell, Robinhood, Novartis, Dell, and More Stocks That Explain Today's Market
AI stocks including Sandisk, Corning, and Intel struggle as investors ditch risk assets amid a run-up in bond yields.
Novartis Shares Climb After Pill Hits Goals in Multiple Sclerosis Trials
Novartis shares rose after the drugmaker reported positive results in two late-stage trials from its new pill for the most common form of multiple sclerosis.
Novartis announces results from Phase III Remodel-1/-2 trials of remibrutinib
Novartis (NVS) announced positive topline results from its Phase III Remodel-1/-2 trials of remibrutinib in relapsing multiple sclerosis. Remibrutinib, a highly selective and potent oral Bruton’s tyro...
Novartis halts autoimmune CAR-T trials following three deaths, Reuters says
Novartis (NVS) has paused eight clinical trials of rap-cel, an experimental cell therapy targeting autoimmune and neurological disorders, after three patients died, Reuters’ Shivani Tanna and Bhanvi S...
Novartis' oral multiple sclerosis drug meets main goal in late stage studies
Swiss drugmaker Novartis said on Tuesday that its oral drug, remibrutinib, met the main goals in two late-stage studies, showing superiority over a rival drug in reducing relapse rates in patie...
Novartis pauses autoimmune cell therapy studies after deaths, WSJ reports
Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late August, after three patients died, the Wall Street Journal reported on Tuesda...
Novartis Pauses Autoimmune Cell Therapy Studies After Deaths
Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late August, after three patients died.
Novartis’ iptacopan granted FDA orphan designation
Novartis (NVS)’ iptacopan was granted FDA orphan designation as a treatment of atypical hemolytic uremic syndrome, according to a post to the agency’s website.
Novartis defeats UK court bid to invalidate blockbuster drug Entresto patent
Swiss drugmaker Novartis on Thursday defeated a bid to invalidate its patent for blockbuster heart drug Entresto, with London's High Court rejecting a claim by Intas Pharmaceuticals' Accord Healthca...
Drugmakers curb Swiss reimbursement applications over US pricing concerns
Drugmakers are holding back applications for health insurance coverage in Switzerland over concerns that lower prices there could affect their U.S. business under drug-pricing policies introduced by ...
Novartis says FDA approves Pluvicto for PSMA+ metastatic prostate cancer
Novartis (NVS) announced the US Food and Drug Administration approved Pluvicto in combination with an androgen receptor pathway inhibitor for patients with prostate-specific membrane antigen-positive ...
3 Dividend Stocks to Buy for a Lifetime of Passive Income
Novartis is expertly handling massive patent cliffs, which speaks volumes about how resilient its business is. Abbott Laboratories has attractive long-term opportunities within its core medical device...
Novartis price target raised to CHF 142 from CHF 132 at Citi
Citi analyst Graham Parry raised the firm’s price target on Novartis (NVS) to CHF 142 from CHF 132 and keeps a Buy rating on the shares.
Novartis CEO on 2Q Profit Beat, Investing in Pipeline
Novartis reported better-than-expected sales and earnings for the second quarter, driven by strong performance from its new cancer medicines which offset declining sales of its former blockbuster drug...
Novartis Q2 Earnings Call Highlights
Novartis NYSE: NVS said it returned to sales growth in the second quarter of 2026, supported by strong gains across priority medicines and launches, while reaffirming its full-year outlook despite con...
Novartis AG Earnings Call Transcript: Q2 2026
Q2 2026 saw 1% net sales growth and flat core operating income, driven by strong performance in key brands and launches, offsetting generic erosion. Full-year guidance is reaffirmed, with growth drivers showing robust momentum and multiple pivotal pipeline readouts expected in H2.
Novartis AG Quarterly report: Q2 2026
Novartis AG has published its Q2 2026 quarterly earnings report on July 21, 2026.
Novartis AG Slides: Q2 2026
Novartis AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 21, 2026.
Novartis AG Earnings release: Q2 2026
Novartis AG released its Q2 2026 earnings on July 21, 2026, summarizing the period's financial results.
Novartis CEO Vas Narasimhan says 'no change of plans'
Novartis chief executive officer Vas Narasimhan said on Tuesday he plans to stick around for the Swiss drugmaker's next phase of growth, ahead of a series of high-stakes trial data expected f...
Novartis reports Q2 core EPS $2.41 vs. $2.42 last year
Reports Q2 net sales $14.41B vs. $14.1B last year. Commenting on Q2 2026 results, Vas Narasimhan, CEO of Novartis (NVS), said: “Novartis delivered a solid second quarter, returning to sales…